Government-Owned Inventions; Availability for Licensing, 72452-72453 [E5-6803]
Download as PDF
<![CDATA[
72452
Federal Register / Vol. 70, No. 232 / Monday, December 5, 2005 / Notices
for formation of a collimated Gaussian
laser beam profile for IOL testing. Third,
the tip serves as a highly sensitive point
receiver of the back reflectance laser
emission. Fourth, the fiber coupler
provides delivery of the spatially
separated back reflected laser emission
to a detector system. The combination of
these unique features of the confocal
fiber-optic laser method provides high
accuracy (exceeding 1 µm) in spatially
locating the IOL focal point and
measuring the IOL power. A unique
feature of this method is that it allows
for measurement of a wide range of both
positive and negative powers including
high-magnification IOL’s with power
greater than ±20 diopters. The simple
and high-sensitive IOL power testing
method will provide the CDRH/FDA
and the scientific community with an
independent source of measurement
data and information for evaluating the
effectiveness and safety of novel IOL
products.
Minimally Immunogenic Variants of
SDR-Grafted Humanized Antibody
CC49 and Their Use
Syed Kashmiri (NCI), Jeffrey Schlom
(NCI), and Eduardo Padlan (NIDDK)
U.S. Provisional Application No. 60/
493,903 filed 29 Aug 2003 (HHS
Reference No. E–323–2003/0-US–01)
and PCT Application No. PCT/US04/
28004 filed 27 Aug 2004 (HHS
Reference No. E–323–2003/0-PCT–
02).
Licensing Contact: Michelle Booden;
301/451–7337;
boodenm@mail.nih.gov.
Tumor Associated Glycoprotein 72
(TAG)–72 is an oncofetal antigen
expressed on a majority of human
carcinomas, including colorectal,
gastric, pancreatic, breast, lung, and
ovarian. The murine monoclonal
antibody (mAb) CC49 specifically
recognizes TAG–72 and has a higher
affinity for TAG–72 than its
predecessor, B72.3.
The present invention relates to
humanized monoclonal antibodies that
have high binding affinity for the tumorassociated glycoprotein (TAG)–72 with
minimal immunogenicity. This antiTAG–72 antibody binds to the same
epitope as the CC49 murine variant
developed at the National Cancer
Institute. The variants of CC49
described in this patent application
have been shown to have a decreased
immune response, with comparable
binding affinity, than the parent murine
antibodies.
These variants have potential benefits
for use in the detection and/or treatment
of a range of human carcinomas. Certain
fields of use may not be available.
VerDate Aug<31>2005
17:14 Dec 02, 2005
Jkt 208001
Please contact OTT for information
regarding the availability of specific
fields of use. This variant was published
in Kashmiri et al., ‘‘Minimizing
Immunogenicity of the SDR-grafted
Humanized Antibody CC49 by Genetic
Manipulation of the Framework
Residues,’’ Molecular Immunology, 40
(2003), 337–349.
Restenosis/Atherosclerosis Diagnosis,
Prophylaxis, and Therapy
Toren Finkel et al. (NHLBI)
U.S. Patent No. 6,183,752 issued 06 Feb
2001 (HHS Reference No. E–258–
1994/0-US–01)
Licensing Contact: Fatima Sayyid; 301/
435–4521; sayyidf@mail.nih.gov.
This technology relates to the
compositions and methods for the
diagnosis, prevention, and therapy of
restenosis and atherosclerosis. It
involves the use of an agent for
decreasing viral load, preferably a
vaccine, against cytomegalovirus (CMV)
and p53, including a method for
providing the therapy and administering
the agent. This invention thus relates to
stimulating an immune response,
preferably a cellular immune response,
directed against CMV and p53 to inhibit
or prevent restenosis, atherosclerosis,
and smooth muscle proliferation.
Therefore, the technology offers
methods for inducing cell death with
the purpose of inhibiting smooth muscle
proliferation as a means of preventing or
treating restenosis and atherosclerosis.
Dated: November 14, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E5–6802 Filed 12–2–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
SUMMARY:
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Mitotic Spindle ASPM as a Diagnostic
Marker for Neoplasia and Uses Thereof
Paul K. Goldsmith, Vladmir Larionov,
Natalay Kouprina and John I. Risinger
(NCI)
U.S. Provisional Application No. 60/
696,212 filed 01 Jul 2005 (HHS
Reference No. E–210–2005/0–US–01)
Licensing Contact: Mojdeh Bahar; 301/
435–2950; baharm@mail.nih.gov.
Cancer is responsible for
approximately 23% of deaths in the
United States of America. A high
percentage of these deaths are caused by
the lack of a precise diagnostic method
that can detect malignancy in a
particular tissue at an early stage. This
invention provides for diagnostic
methods, compositions, and kits that are
useful for identifying neoplasia by
measuring Abnormal Spindle-like
Microcephaly associated (ASPM)
expression in a patient sample. The
ASPM gene is the human ortholog of the
Drosophila melanogaster ‘abnormal
spindle’ gene (asp), which is essential
for normal mitotic spindle function in
embryonic neuroblasts. By measuring
ASPM expression levels one can also
determine if a particular subject has a
higher propensity to develop neoplasia.
This invention is particularly useful in
detecting neoplasia in hard to diagnose
cancers like ovarian and uterine cancer.
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors.
Monoclonal Antibodies That Bind or
Neutralize Hepatitis B Virus
Robert H. Purcell (NIAID) et al.
U.S. Provisional Application No. 60/
644,309 filed 14 Jan 2005 (HHS
Reference No. E–144–2004/0-US–01)
Licensing Contact: Chekesha S.
Clingman; 301/435–5018;
clingmac@mail.nih.gov..
Hepatitis B virus (HBV) chronically
infects over 300 million people
worldwide. Many of them will die of
chronic hepatitis or hepatocellular
E:\FR\FM\05DEN1.SGM
05DEN1
Federal Register / Vol. 70, No. 232 / Monday, December 5, 2005 / Notices
carcinoma. The present technology
relates to the isolation and
characterization of a novel neutralizing
chimpanzee monoclonal antibody to
HBV. The antibody was identified
through a combinatorial antibody
library constructed from bone marrow
cells of a chimpanzee experimentally
infected with HBV. The selected
monoclonal antibody has been shown to
react equally well with wild-type HBV
and the most common neutralization
escape mutant variants. Therefore, this
monoclonal antibody with high affinity
and broad reactivity may have distinct
advantages over other approaches to
immunoprophylaxis and
immunotherapy of chronic HBV
infection, as most of the monoclonal
antibodies currently in use are not
sufficiently and broadly reactive to
prevent the emergence of neutralization
escape mutants of HBV. This technology
describes such antibodies, fragments of
such antibodies retaining hepatitis B
virus-binding ability, fully human or
humanized antibodies retaining
hepatitis B virus-binding ability, and
pharmaceutical compositions including
such antibodies. This invention further
describes isolated nucleic acids
encoding the antibodies and host cells
transformed with nucleic acids. In
addition, this invention provides
methods of employing these antibodies
and nucleic acids in the in vitro and in
vivo diagnosis, prevention and therapy
of HBV diseases.
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors.
Polypeptide Multimers Having
Antiviral Activity
Carol Weiss et al. (FDA)
PCT Application No. PCT/US03/25295
filed 14 Aug 2003, which published
as WO 2005/018666 on 03 Mar 2005
(HHS Reference No. E–155–2003/0PCT–01)
Licensing Contact: Susan Ano; 301/435–
5515; anos@mail.nih.gov.
The technology describes polypeptide
multimers that have antiviral and
immunogenic activity against HIV.
These multimers consist of at least one
monomer of the highly conserved N and
C heptad regions of gp41 in a ratio of at
least 2:1 N to C heptad, with the N and
C heptads being connected by linkers.
The monomer forms homodimers and
homotrimers in solution and mimic
fusion intermediate structure. Further,
the technology also describes a method
of raising a broadly neutralizing
antibody response to HIV by
administering the polypeptide
VerDate Aug<31>2005
17:14 Dec 02, 2005
Jkt 208001
multimers mentioned above. Thus,
these polypeptide multimers may be
used as antiviral (anti-HIV) agents.
Because the structure of these
polypeptide multimers mimics the gp41
fusion intermediate, they can also be
used to identify compounds that may
inhibit the fusion process.
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors.
Dated: November 15, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E5–6803 Filed 12–2–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the meeting of the
Advisory Committee to the Director,
National Institutes of Health (NIH).
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
A portion of the meeting will be
closed to the public in accordance with
the provisions set forth in sections
552b(c)(6) and 552b(c)(9)(B), Title 5
U.S.C., as amended, because the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy and the premature
disclosure of information and the
discussions would likely to significantly
frustrate implementation of the
program.
Name of Committee: Advisory Committee
to the Director, NIH.
Date: December 1–2, 2005.
Closed: December 1, 2005, 8:30 a.m. to 9:45
a.m.
Agenda: Office of Portfolio Analysis and
Strategic Initiatives (OPASI).
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, Conference
Room 6, Bethesda, MD 20892.
Open: December 1, 2005, 10 a.m. to 4:30
p.m.
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
72453
Agenda: Among the topics proposed for
discussion are: (1) NIH Director’s Report; (2)
Clinical and Translational Science Awards;
(3) NIH Director’s Council of Public
Representatives Liaison Report; and (4)
update on NIH Neurosciences Blueprint.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, Conference
Room 6, Bethesda, MD 20892.
Open: December 2, 2005, 9 a.m. to 12 p.m.
Agenda: Among the topics proposed for
discussion are: (1) Office of Portfolio
Analysis and Strategic Initiatives (OPASI); (2)
Public Access Update; and (3) Workgroup
Report on Outside Awards for NIH
Employees.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, Conference
Room 6, Bethesda, MD 20892.
Contact Person: Shelly Pollard, ACD
Coordinator, Office of Communications and
Public Liaison, Office of the Director,
National Institutes of Health, 31 Center Drive,
Building 31, Room 5B64, Bethesda, MD
20892, Phone: (301) 496–0959,
pollards@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
into the building by non-government
employees. Persons without a government
I.D. will need to show a photo I.D. and signin at the security desk upon entering the
building.
Information is also available on the
Institute’s/Center’s home page: https://
www.nih.gov/about/director/acd.htm where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: November 22, 2005.
Nancy Middendorf,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–23590 Filed 12–2–05; 8:45 am]
BILLING CODE 4140–01–M
E:\FR\FM\05DEN1.SGM
05DEN1
]]>Agencies
[Federal Register Volume 70, Number 232 (Monday, December 5, 2005)]
[Notices]
[Pages 72452-72453]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E5-6803]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Mitotic Spindle ASPM as a Diagnostic Marker for Neoplasia and Uses
Thereof
Paul K. Goldsmith, Vladmir Larionov, Natalay Kouprina and John I.
Risinger (NCI)
U.S. Provisional Application No. 60/696,212 filed 01 Jul 2005 (HHS
Reference No. E-210-2005/0-US-01)
Licensing Contact: Mojdeh Bahar; 301/435-2950; baharm@mail.nih.gov.
Cancer is responsible for approximately 23% of deaths in the United
States of America. A high percentage of these deaths are caused by the
lack of a precise diagnostic method that can detect malignancy in a
particular tissue at an early stage. This invention provides for
diagnostic methods, compositions, and kits that are useful for
identifying neoplasia by measuring Abnormal Spindle-like Microcephaly
associated (ASPM) expression in a patient sample. The ASPM gene is the
human ortholog of the Drosophila melanogaster `abnormal spindle' gene
(asp), which is essential for normal mitotic spindle function in
embryonic neuroblasts. By measuring ASPM expression levels one can also
determine if a particular subject has a higher propensity to develop
neoplasia. This invention is particularly useful in detecting neoplasia
in hard to diagnose cancers like ovarian and uterine cancer.
In addition to licensing, the technology is available for further
development through collaborative research opportunities with the
inventors.
Monoclonal Antibodies That Bind or Neutralize Hepatitis B Virus
Robert H. Purcell (NIAID) et al.
U.S. Provisional Application No. 60/644,309 filed 14 Jan 2005 (HHS
Reference No. E-144-2004/0-US-01)
Licensing Contact: Chekesha S. Clingman; 301/435-5018;
clingmac@mail.nih.gov..
Hepatitis B virus (HBV) chronically infects over 300 million people
worldwide. Many of them will die of chronic hepatitis or hepatocellular
[[Page 72453]]
carcinoma. The present technology relates to the isolation and
characterization of a novel neutralizing chimpanzee monoclonal antibody
to HBV. The antibody was identified through a combinatorial antibody
library constructed from bone marrow cells of a chimpanzee
experimentally infected with HBV. The selected monoclonal antibody has
been shown to react equally well with wild-type HBV and the most common
neutralization escape mutant variants. Therefore, this monoclonal
antibody with high affinity and broad reactivity may have distinct
advantages over other approaches to immunoprophylaxis and immunotherapy
of chronic HBV infection, as most of the monoclonal antibodies
currently in use are not sufficiently and broadly reactive to prevent
the emergence of neutralization escape mutants of HBV. This technology
describes such antibodies, fragments of such antibodies retaining
hepatitis B virus-binding ability, fully human or humanized antibodies
retaining hepatitis B virus-binding ability, and pharmaceutical
compositions including such antibodies. This invention further
describes isolated nucleic acids encoding the antibodies and host cells
transformed with nucleic acids. In addition, this invention provides
methods of employing these antibodies and nucleic acids in the in vitro
and in vivo diagnosis, prevention and therapy of HBV diseases.
In addition to licensing, the technology is available for further
development through collaborative research opportunities with the
inventors.
Polypeptide Multimers Having Antiviral Activity
Carol Weiss et al. (FDA)
PCT Application No. PCT/US03/25295 filed 14 Aug 2003, which published
as WO 2005/018666 on 03 Mar 2005 (HHS Reference No. E-155-2003/0-PCT-
01)
Licensing Contact: Susan Ano; 301/435-5515; anos@mail.nih.gov.
The technology describes polypeptide multimers that have antiviral
and immunogenic activity against HIV. These multimers consist of at
least one monomer of the highly conserved N and C heptad regions of
gp41 in a ratio of at least 2:1 N to C heptad, with the N and C heptads
being connected by linkers. The monomer forms homodimers and
homotrimers in solution and mimic fusion intermediate structure.
Further, the technology also describes a method of raising a broadly
neutralizing antibody response to HIV by administering the polypeptide
multimers mentioned above. Thus, these polypeptide multimers may be
used as antiviral (anti-HIV) agents. Because the structure of these
polypeptide multimers mimics the gp41 fusion intermediate, they can
also be used to identify compounds that may inhibit the fusion process.
In addition to licensing, the technology is available for further
development through collaborative research opportunities with the
inventors.
Dated: November 15, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E5-6803 Filed 12-2-05; 8:45 am]
BILLING CODE 4140-01-P
